Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
COLYTE vs ALPHACAINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Bowel preparation prior to colonoscopy,Bowel preparation prior to barium enema,Bowel preparation prior to colorectal surgery
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
Not applicable; systemic absorption is negligible (<0.06%), so a terminal elimination half-life is clinically irrelevant. The gastrointestinal transit time for the solution is approximately 1-3 hours.
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Polyethylene glycol is not significantly metabolized and is excreted largely unchanged in feces.
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
COLYTE (polyethylene glycol 3350 and electrolytes) is minimally absorbed; <0.1% of the dose is excreted renally. The majority is eliminated unchanged in feces via the gastrointestinal tract, with fecal excretion accounting for >99%.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Not applicable; negligible systemic absorption, so protein binding is clinically irrelevant.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
Not applicable; negligible systemic absorption, so volume of distribution is clinically irrelevant.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
Oral: <0.1% (systemic bioavailability is negligible due to minimal absorption of polyethylene glycol).
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
No dose adjustment required for renal impairment; use with caution in severe renal insufficiency (Cr Cl <30 m L/min) due to potential electrolyte imbalance.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
No specific dose adjustments for hepatic impairment; use with caution in severe hepatic disease.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Pediatric patients (≥6 months): 25-40 m L/kg/hour orally or via nasogastric tube until rectal effluent is clear; maximum 4 L.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
No specific dose adjustment; monitor for dehydration and electrolyte disturbances due to reduced renal reserve.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
None
There is no FDA black box warning for ALPHACAINE.
Risk of electrolyte disturbances (especially in patients with renal impairment or those taking medications affecting electrolytes), aspiration risk (use with caution in patients with impaired gag reflex or at risk of regurgitation), serious fluid and electrolyte abnormalities, cardiac arrhythmias, seizures, and serious adverse reactions including ischemic colitis and ulcerative colitis. Use with caution in patients with severe ulcerative colitis, toxic megacolon, or gastrointestinal obstruction.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Gastrointestinal obstruction, bowel perforation, toxic megacolon, gastric retention, ileus, known hypersensitivity to any component of the product.
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
Avoid all solid foods during bowel preparation; only clear liquids (e.g., water, clear broth, apple juice, black coffee, clear soda) are permitted. Dairy products, red or purple liquids (which can mimic blood), and alcohol should be avoided. Resume a normal diet only after the procedure.
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for fetal harm due to maternal dehydration or electrolyte imbalance.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Not known if excreted in human milk. M/P ratio not determined. Caution advised due to potential for diarrhea in nursing infant. Use only if clearly needed.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
No specific dose adjustments recommended. Pharmacokinetic changes in pregnancy not studied; standard bowel preparation dosing should be used with caution due to increased risk of fluid and electrolyte shifts.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
Colyte (PEG-3350 with electrolytes) is used for bowel cleansing prior to colonoscopy. Ensure adequate hydration to prevent electrolyte imbalances. Administer in divided doses; split-dose regimen improves tolerability and cleansing quality. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon. Monitor for bloating, nausea, and vomiting; slow rate if symptoms occur.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Follow the prescribed dosing schedule exactly; do not skip doses.,Drink the entire solution as directed, typically with a split-dose regimen (half the evening before, half the morning of the procedure).,Stay well-hydrated; drink clear liquids after starting the preparation.,Avoid solid foods; only clear liquids are allowed until after the procedure.,Expect frequent, watery bowel movements; this is necessary for cleansing.,Notify your doctor if you experience severe bloating, vomiting, or signs of dehydration.,Do not take other medications within 1 hour of starting the preparation.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about COLYTE vs ALPHACAINE, answered by our medical review team.
COLYTE is a Osmotic Laxative that works by Colyte is a polyethylene glycol (PEG)-based osmotic laxative that induces diarrhea by retaining water in the gastrointestinal tract via osmotic forces, thereby cleansing the colon.. ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between COLYTE and ALPHACAINE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of COLYTE is: 4 L oral solution administered as a single dose at a rate of 240 m L every 10 minutes until complete.. The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between COLYTE and ALPHACAINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. COLYTE is classified as Category C. Category C. No adequate and well-controlled studies in pregnant women. Animal studies have not been conducted. Should be used during pregnancy only if clearly needed. Potential for. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.